CD274 and neoplasm: A phase Ib, placebo-controlled, randomized KEYNOTE-012 [16], tested the safety and efficacy of pembrolizumab treatment with any level of PD-L1 expression (at least 1% of tumor cells or stroma positive by immunohistochemistry for PD-L1) in the HNSCC.